Pharmacists in Mission, Kansas


13 Pharmacists found in Mission
female pharmacist

Amanda Belmont, PHARMD


Pharmacist
6655 Martway St, Mission, KS 66202
913-831-4477     913-831-9263

female pharmacist

Anne M Alley, PHARMD


Pharmacist
6655 Martway St, Mission, KS 66202
913-831-4477    

female pharmacist

Ashley Stclair


Pharmacist
6100 Broadmoor St, Mission, KS 66202
913-262-7863    



male pharmacist

Brandon Huningahke


Pharmacist
6655 Martway St, Mission, KS 66202
913-831-4477     913-831-9263

female pharmacist

Courtney C Reddell, PHARM D


Pharmacist
6100 Broadmoor St, Mission, KS 66202
913-262-7863     913-262-7863

male pharmacist

Dr. Danny Nguyen, PHARM D


Pharmacist
6100 Broadmoor St, Mission, KS 66202
913-262-7863    

male pharmacist

Elham Shaiwani


Pharmacist
6655 Martway St, Mission, KS 66202
913-831-4447    

male pharmacist

Mr. Eric Everett, RPH


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
5453 W 61st Pl, Mission, KS 66205
913-322-0001     913-322-0002

male pharmacist

Gregory Schmack


Pharmacist
6100 Broadmoor St, Mission, KS 66202
913-262-7863    

male pharmacist

Joshua Moorehead


Pharmacist
6300 Johnson Dr, Mission, KS 66202
913-722-3711    

female pharmacist

Dr. Lauren Marie Moles, PHARM.D.


Pharmacist
6300 Johnson Dr, Mission, KS 66202
913-722-3711     913-677-5645

female pharmacist

Lisa G Everett, RPH


Pharmacist - Nutrition Support
5453 W 61st Pl, Mission, KS 66205
913-322-0001     913-322-0001

female pharmacist

Dr. Ly Smith, PHARM.D.


Pharmacist
6100 Broadmoor St, Mission, KS 66202
913-262-7863     913-553-6310


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.